8IG6

Crystal structure of MERS main protease in complex with GC376


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.07 Å
  • R-Value Free: 0.233 
  • R-Value Work: 0.193 
  • R-Value Observed: 0.195 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Structural Basis for Coronaviral Main Proteases Inhibition by the 3CLpro Inhibitor GC376.

Lin, C.Zhu, Z.Jiang, H.Zou, X.Zeng, X.Wang, J.Zeng, P.Li, W.Zhou, X.Zhang, J.Wang, Q.Li, J.

(2024) J Mol Biol 436: 168474-168474

  • DOI: https://doi.org/10.1016/j.jmb.2024.168474
  • Primary Citation of Related Structures:  
    8IG4, 8IG5, 8IG6, 8IG7, 8IG8, 8IG9, 8IGA, 8IGB

  • PubMed Abstract: 

    The main protease (M pro ) of coronaviruses participates in viral replication, serving as a hot target for drug design. GC376 is able to effectively inhibit the activity of M pro , which is due to nucleophilic addition of GC376 by binding covalently with Cys145 in M pro active site. Here, we used fluorescence resonance energy transfer (FRET) assay to analyze the IC 50 values of GC376 against M pro s from six different coronaviruses (SARS-CoV-2, HCoV-229E, HCoV-HUK1, MERS-CoV, SARS-CoV, HCoV-NL63) and five M pro mutants (G15S, M49I, K90R, P132H, S46F) from SARS-CoV-2 variants. The results showed that GC376 displays effective inhibition to various coronaviral M pro s and SARS-CoV-2 M pro mutants. In addition, the crystal structures of SARS-CoV-2 M pro (wide type)-GC376, SARS-CoV M pro -GC376, MERS-CoV M pro -GC376, and SARS-CoV-2 M pro mutants (G15S, M49I, S46F, K90R, and P132H)-GC376 complexes were solved. We found that GC376 is able to fit into the active site of M pro s from different coronaviruses and different SARS-CoV-2 variants properly. Detailed structural analysis revealed key molecular determinants necessary for inhibition and illustrated the binding patterns of GC376 to these different M pro s. In conclusion, we not only proved the inhibitory activity of GC376 against different M pro s including SARS-CoV-2 M pro mutants, but also revealed the molecular mechanism of inhibition by GC376, which will provide scientific guidance for the development of broad-spectrum drugs against SARS-CoV-2 as well as other coronaviruses.


  • Organizational Affiliation

    College of Pharmacy, Gannan Medical University, Ganzhou 341000, China.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
ORF1a
A, B
303Middle East respiratory syndrome-related coronavirusMutation(s): 0 
UniProt
Find proteins for K9N7C7 (Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012))
Explore K9N7C7 
Go to UniProtKB:  K9N7C7
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupK9N7C7
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
UED (Subject of Investigation/LOI)
Query on UED

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
N~2~-[(benzyloxy)carbonyl]-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-leucinamide
C21 H31 N3 O5
JUCVXDDMQHPCKT-BZSNNMDCSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.07 Å
  • R-Value Free: 0.233 
  • R-Value Work: 0.193 
  • R-Value Observed: 0.195 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 49.701α = 90
b = 105.99β = 108.548
c = 58.256γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
XDSdata scaling
PHENIXphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2024-03-06
    Type: Initial release
  • Version 1.1: 2024-05-08
    Changes: Database references
  • Version 1.2: 2024-10-30
    Changes: Structure summary